Dysregulation of Noradrenergic Activity: Its Role in Conceptualizing and Treating Major Depressive Disorder, Schizophrenia, Agitation in Alzheimer's Disease, and Posttraumatic Stress Disorder.
Level 5 - mechanism / opinion, no new human data
Expert consensus narrative review without systematic review methodology.
PubMed 39514646 · doi:10.4088/JCP.plunaro2417ah
What was done
A consensus panel of five experts reviewed literature regarding altered noradrenergic signaling and its mechanistic role across major depressive disorder, schizophrenia, agitation in Alzheimer's disease, and posttraumatic stress disorder. This Academic Highlights article summarizes their discussion and conclusions.
What was found
The abstract reports no numerical findings or statistical measures. It presents the panel's qualitative conclusion that noradrenergic abnormalities across psychiatric disorders are best understood as complex dysregulation—encompassing both hyperactivity and deficit states—which may drive symptoms such as agitation, irritability, hyperarousal, and insomnia.
Why it matters
It emphasizes the underappreciated role of norepinephrine signaling relative to serotonin and dopamine, supporting a pathophysiologically targeted approach to managing transdiagnostic symptoms like hyperarousal and agitation.
Limits
The publication represents narrative expert opinion rather than an empirical trial or systematic review. The abstract provides no systematic literature search protocol, no primary outcome data, and no quantitative efficacy metrics for proposed targeted treatments.
Cited by
- contradicts A deficit in norepinephrine causes psychomotor retardation in depressed individuals, keeping them effectively paralyzed.